Compared to 70-GS low-risk patients, the 70-GS high-risk patients had less cardiovascular co-morbidity (12.9% vs 27.3%, p = 0.034), more grade 3 BC (19.4% vs 4.5%, p = 0.006), lower progesterone receptor (PR) positive percentage (53.92 ± 36.49% vs 68.83 ± 30.43%, p = 0.007), more Ki67 high BC (≥ 20%, 87.1% vs 45.5%, p < 0.001) (Table 1). This evidence concerns the gene PGR and breast cancer.